AK-105 / Asahi Kasei - LARVOL DELTA

[VIRTUAL] Efficacy and safety of penpulimab (AK105), a new generation antiprogrammed cell death1 (PD1) antibody, in upper gastrointestinal cancers (ESMO Asia 2020) - P1/2, P1a/1b, P3 | "NCT03352531; NCT04172506. Penpulimab in combination with anlotinib, a multi-targeted receptor tyrosine kinase inhibitor, is being evaluated in phase III studies for 1L HCC (NCT04344158) and 2L Gastric/GEJ (NCT04385550). Akeso Biopharma Inc."

Clinical • Endocrine Disorders • Gastrointestinal Cancer • Gastrointestinal Disorder • Hypertension • Immune Modulation • Inflammation • Nephrology • Oncology • Renal Disease • Solid Tumor

[VIRTUAL] Efficacy and safety of penpulimab (AK105), a new generation antiprogrammed cell death1 (PD1) antibody, in upper gastrointestinal cancers (ESMO Asia 2020) - P1/2, P1a/1b, P3 | "NCT03352531; NCT04172506. Penpulimab in combination with anlotinib, a multi-targeted receptor tyrosine kinase inhibitor, is being evaluated in phase III studies for 1L HCC (NCT04344158) and 2L Gastric/GEJ (NCT04385550). Akeso Biopharma Inc."

Clinical • Endocrine Disorders • Gastrointestinal Cancer • Gastrointestinal Disorder • Hypertension • Immune Modulation • Inflammation • Nephrology • Oncology • Renal Disease • Solid Tumor

[VIRTUAL] Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers (ESMO Asia 2020) - P1/2, P1a/1b, P3 | "Penpulimab in combination with anlotinib, a multi-targeted receptor tyrosine kinase inhibitor, is being evaluated in phase III studies for 1L HCC (NCT04344158) and 2L Gastric/GEJ (NCT04385550). Funding: Akeso Biopharma Inc. Clinical trial identification: NCT03352531; NCT04172506."

Clinical • Endocrine Disorders • Gastrointestinal Cancer • Gastrointestinal Disorder • Hypertension • Immune Modulation • Inflammation • Nephrology • Oncology • Renal Disease • Solid Tumor

Mitochondria-targeted therapeutics, MitoQ and BGP-15, reverse aging-associated meiotic spindle defects in mouse and human oocytes. (PubMed, Hum Reprod) - "was supported by the Iraqi Higher Education and Scientific Research Ministry PhD scholarship and O.C. was supported by TUBITAK-1059B191601275. is an inventor on patents relating to the use of BGP-15 to improve gamete quality. N/A."

Journal • Metabolic Disorders • CEACAM1

A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (clinicaltrials.gov) - P2; N=206; Recruiting; Sponsor: Akeso

Clinical • Combination therapy • New P2 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: Akeso

Clinical • Combination therapy • New P2 trial • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - P2; N=30; Active, not recruiting; Sponsor: Akeso; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer (clinicaltrials.gov) - P2; N=140; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Jan 2020 ➔ May 2020

Clinical • Enrollment open • Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer • Thymus Cancer

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors (clinicaltrials.gov) - P2; N=150; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Jan 2020 ➔ Jun 2020

Clinical • Enrollment open • Trial initiation date • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - P3; N=648; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P3 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P3; N=528; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P3 trial • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor (clinicaltrials.gov) - P2; N=138; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • Mismatch Repair • New P2 trial • MSI-H

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors (clinicaltrials.gov) - P2; N=140; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P2 trial

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer (clinicaltrials.gov) - P2; N=140; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P2 trial

Mechanism of β-carboline alkaloids inhibiting migration and invasion of SGC-7901 cells (PubMed, Zhongguo Zhong Yao Za Zhi) - "To explore the mechanism of β-carboline alkaloids inhibiting the migration and invasion of SGC-7901 cells and its correlation with FAK gene expression,CCK-8 method was used to determine the inhibitory rate of β-carboline alkaloids on the proliferation of gastric cancer SGC-7901 cells under different concentrations.The effect of β-carboline alkaloids on the migration and invasion of SGC-7901 cells was used by Transwell compartment.Detection of mRNA and protein expression of FAK genes were used by qRT-PCR and Western blot.Then si-FAK-1051 recombinant plasmid was transfected into SGC-7901 cells.FAK gene silencing effect was identified by qRT-PCR and Western blot technique again.Finally,the effects of FAK gene silencing on proliferation and migration of gastric cancer SGC-7901 cells were detected by CCK-8 kit and Transwell chamber assay respectively.With the increase of the concentration ofβ-carboline alkaloids,the inhibitory rate of SGC-7901 cells in human gastric cancer..."

Journal

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P3; N=338; Recruiting; Sponsor: Akeso

Clinical • New P3 trial

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - P2; N=153; Recruiting; Sponsor: Akeso

Clinical • New P2 trial

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P3; N=360; Recruiting; Sponsor: Akeso

Clinical • New P3 trial